Long-term Management of AMD. Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan
|
|
- Molly Kelley
- 5 years ago
- Views:
Transcription
1 Long-term Management of AMD Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan
2 DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized by one of the following: Presence of at least intermediate-size drusen ( 63 μm in diameter) Retinal pigment epithelium (RPE) abnormalities (hypo/hyperpigmentation) Reticular pseudodrusen Presence of any of the following features: Geographic atrophy (GA) of the RPE Choroidal neovascularization (CNV) (exudative, wet) Polypoidal choroidal vasculopathy (PCV) Retinal Angiomatous Proliferation (RAP) 1. Ferris FL III, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology 2013
3 DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized by one of the following: Presence of at least intermediate-size drusen ( 63 μm in diameter) Retinal pigment epithelium (RPE) abnormalities (hypo/hyperpigmentation) Reticular pseudodrusen Presence of any of the following features: Geographic atrophy (GA) of the RPE Choroidal neovascularization (CNV) (exudative, wet) Polypoidal choroidal vasculopathy (PCV) Retinal Angiomatous Proliferation (RAP) 1. Ferris FL III, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology 2013
4 DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized by one of the following: Presence of at least intermediate-size drusen ( 63 μm in diameter) Retinal pigment epithelium (RPE) abnormalities (hypo/hyperpigmentation) Reticular pseudodrusen Presence of any of the following features: Geographic atrophy (GA) of the RPE Choroidal neovascularization (CNV) (exudative, wet) Polypoidal choroidal vasculopathy (PCV) Retinal Angiomatous Proliferation (RAP) Courtesy of Isabelle Aknin 1. Ferris FL III, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology 2013
5 DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized by one of the following: Presence of at least intermediate-size drusen ( 63 μm in diameter) Retinal pigment epithelium (RPE) abnormalities (hypo/hyperpigmentation) Reticular pseudodrusen Presence of any of the following features: Geographic atrophy (GA) of the RPE Choroidal neovascularization (CNV) (exudative, wet) Polypoidal choroidal vasculopathy (PCV) Retinal Angiomatous Proliferation (RAP) Courtesy of M. Mauget-Faÿsse 1. Ferris FL III, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology 2013
6 DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized by one of the following: Presence of at least intermediate-size drusen ( 63 μm in diameter) Retinal pigment epithelium (RPE) abnormalities (hypo/hyperpigmentation) Reticular pseudodrusen Presence of any of the following features: Geographic atrophy (GA) of the RPE Choroidal neovascularization (CNV) (exudative, wet) Polypoidal choroidal vasculopathy (PCV) Retinal Angiomatous Proliferation (RAP) 1. Ferris FL III, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology 2013
7 Guidelines For The Management of AMD PREVALENCE
8 Guidelines For The Management of AMD PREVALENCE
9
10 Prevalence 2 Leading cause of severe, irreversible vision impairment in developed countries: o USA in 2004: 1.75 M 40 yo neovascular AMD/geographic atrophy in at least 1 eye 7.3 M have high risk features (large drusen 125 μm) o USA in 2020: 3 M 40 yo neovascular AMD/geographic atrophy in at least 1 eye Antioxidants vitamins (e.g. vitamin C, vitamin E), lutein, zeaxanthin, and zinc progression AMD by approximately 25% at 5 years 2. Congdon N, O Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the united states. Arch Ophthl
11 Prevalence 3 3. Klein R, Klein BE, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophth
12 AMD is responsible for an estimated 46% of cases of severe visual loss (VA 20/200) o Although 80% of AMD patients have the nonneovascular (atrophic) form o The neovascular form is responsible for 90% of the severe VA loss
13 Guidelines For The Management of AMD RISK FACTORS
14 Risk Factors 4 Age ( 75 yo) Race (caucasians) Smoking o Dose response relationship o R AMD in subjects who did not smoke 20y = R AMD in nonsmokers o Smoking cessation is strongly recommended o Hypertension & other cardiovascular diseases are not risk factors 4. Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, SanGiovanni JP, Ferris FL, et al. Lutein/Zeaxanthin for the treatment of age-related cataract: AREDS 2 randomized trial report number 4. JAMA Ophthalmol 2013;131:843-50
15 Levels of antioxidants o Inconsistent data in identifying low levels of plasma levels o Antioxidants vitamins (Vit C, Vit A, beta-carotene) + zinc progression AMD by 25% at 5 years o Replacement of beta-carotene with lutein/zeaxanthin in the new AREDS2 formulation o competitive absorption of lutein/zeaxanthin o incidence lung cancer in smokers
16 Diet o incidence dietary intake of foods rich in omega-3 longchain polyunsaturated fatty acids (fish) o Not necessarily in the form of supplement o incidence with higher intake of saturated fat o incidence BMI
17 Risk Factors 5 Aspirin o Meta-analysis did not show a risk of AMD Genetic factors (Evidence I ++, I + & I - ) o Complement Factor H (CFH) Y401H polymorphism on chromosome 1( 7.4x) o ARMS2/HtrA1 gene o Hepatic Lipase (LIPC) gene o Rs variant in the toll-like receptor 3 (TLR3) gene 5. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:421-4
18
19
20 Risk Factors 5 Other risk factors o Waist/hip ratio for men o Hormonal status o Sunlight exposure o Markers of inflammation: C-reactive protein, erythrocyte sedimentation rate o Alcohol use o Vitamins B & D status, Calcium? 5. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science
21 Guidelines For The Management of AMD DIAGNOSIS
22 DIAGNOSIS History Symptoms o Metamorphopsia o Decreased vision o Photopsia o Difficulties in dark adaptation Medication and nutrition supplement use Ocular history Medical history (including hypersensitivity reactions) Family history (AMD) Social history (Smoking) Physical examination Comprehensive eye examination Stereoscopic biomicroscopic examination of the macula
23 DIAGNOSIS Diagnostic tests Spectral Domain Optical Coherence Tomography o OCT-Angiography (quiescent vs. active lesions?) Fundus Fluorescein Angiography Fundus Photography Indocyanine Green Angiography o PED, Occult CNV, PCV, RAP Other tests Fundus Autofluorescence o Geographic atrophy/lipofuscin Microperimetry Adaptative Optics
24 Guidelines For The Management of AMD CLASSIFICATION
25 CLASSIFICATION 6 No AMD Early AMD Intermediate AMD Advanced AMD (AREDS category 1) (AREDS category 2) (AREDS category 3) (AREDS category 4) Control group No or few small drusen (< 63μm) Multiple small drusen Few intermediate drusen ( μm) Mild RPE abnormalities Numerous intermediate drusen At lease one large druse ( 125 μm) Geographic atrophy of the RPE (Not involving the center of the fovea) Geographic atrophy of the RPE involving the center of the fovea Neovascular maculopathy: CNV (pathologic angiogenesis from the choroidal vasculature extending the a defect in Bruch s membrane Serous/hemorrhagic detachement of NSR/RPE Retinal hard exudates Subretinal/sub-RPE fibrovascular proliferation Disciform scar 6. Age-related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report number 8. Arch Ophthalmol 2001;119:
26 CLASSIFICATION 6 No AMD Early AMD Intermediate AMD Advanced AMD (AREDS category 1) (AREDS category 2) (AREDS category 3) (AREDS category 4) Control group No or few small drusen (< 63μm) Multiple small drusen Few intermediate drusen ( μm) Mild RPE abnormalities Numerous intermediate drusen At lease one large druse ( 125 μm) Geographic atrophy of the RPE (Not involving the center of the fovea) Geographic atrophy of the RPE involving the center of the fovea Neovascular maculopathy: CNV (pathologic angiogenesis from the choroidal vasculature extending the a defect in Bruch s membrane Serous/hemorrhagic detachement of NSR/RPE Retinal hard exudates Subretinal/sub-RPE fibrovascular proliferation Disciform scar 6. Age-related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report number 8. Arch Ophthalmol 2001;119:
27 CLASSIFICATION 6 No AMD Early AMD Intermediate AMD Advanced AMD (AREDS category 1) (AREDS category 2) (AREDS category 3) (AREDS category 4) Control group No or few small drusen (< 63μm) Multiple small drusen Few intermediate drusen ( μm) Mild RPE abnormalities Numerous intermediate drusen At lease one large druse ( 125 μm) Geographic atrophy of the RPE (Not involving the center of the fovea) Geographic atrophy of the RPE involving the center of the fovea Neovascular maculopathy: CNV (pathologic angiogenesis from the choroidal vasculature extending the a defect in Bruch s membrane Serous/hemorrhagic detachement of NSR/RPE Retinal hard exudates Subretinal/sub-RPE fibrovascular proliferation Disciform scar 6. Age-related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report number 8. Arch Ophthalmol 2001;119:
28 CLASSIFICATION 6 No AMD Early AMD Intermediate AMD Advanced AMD (AREDS category 1) (AREDS category 2) (AREDS category 3) (AREDS category 4) Control group No or few small drusen (< 63μm) Multiple small drusen Few intermediate drusen ( μm) Mild RPE abnormalities Numerous intermediate drusen At lease one large druse ( 125 μm) Geographic atrophy of the RPE (Not involving the center of the fovea) Geographic atrophy of the RPE involving the center of the fovea Neovascular maculopathy: CNV (pathologic angiogenesis from the choroidal vasculature extending the a defect in Bruch s membrane Serous/hemorrhagic detachement of NSR/RPE Retinal hard exudates Subretinal/sub-RPE fibrovascular proliferation Disciform scar 6. Age-related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report number 8. Arch Ophthalmol 2001;119:
29 CLASSIFICATION 6 No AMD Early AMD Intermediate AMD Advanced AMD (AREDS category 1) (AREDS category 2) (AREDS category 3) (AREDS category 4) Control group No or few small drusen (< 63μm) Multiple small drusen Few intermediate drusen ( μm) Mild RPE abnormalities Numerous intermediate drusen At lease one large druse ( 125 μm) Geographic atrophy of the RPE (Not involving the center of the fovea) Geographic atrophy of the RPE involving the center of the fovea Neovascular maculopathy: CNV (pathologic angiogenesis from the choroidal vasculature extending the a defect in Bruch s membrane Serous/hemorrhagic detachement of NSR/RPE Retinal hard exudates Subretinal/sub-RPE fibrovascular proliferation Disciform scar 6. Age-related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report number 8. Arch Ophthalmol 2001;119:
30 Guidelines For The Management of AMD NATURAL HISTORY
31 NATURAL HISTORY 7 No AMD Early AMD Intermediate AMD Advanced AMD (AREDS category 1) (AREDS category 2) (AREDS category 3) (AREDS category 4) 15% large 10 y 15% large 10 y When medium drusen are present in 1 eye: 37% large 10 y Beaver Dam Eye Study 22% neovascular/geographic atrophy in the fellow eye involving the 5 y When medium drusen are present in 2 eyes: 71% large 10 y AREDS 35%-50% neovascular/geographic atrophy in the fellow eye involving the 5 y 7. Chew EY, Clemons TE, Agron E, et al. Age-related Eye Disease Study Research Group. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report number 36. JAMA Ophthalmol 2014;132:272-7
32 NATURAL HISTORY 8 Simplified severity scale 8. Ferris FL, Davis MD, Seddon JM, et al. Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for agerelated macular degeneration: AREDS report number 18. Arch Ophthalmol 2005;123:1570-4
33 NATURAL HISTORY 8 Simplified severity scale This simplified severity scale enables the clinician to communicate with the patient about his/her approximate risk for developing advanced AMD 8. Ferris FL, Davis MD, Seddon JM, et al. Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for agerelated macular degeneration: AREDS report number 18. Arch Ophthalmol 2005;123:1570-4
34 Guidelines For The Management of AMD RATIONALE FOR TREATMENT
35 Guidelines For The Management of AMD RATIONALE FOR TREATMENT Prospective randomized controlled clinical trials support the use of antioxidant vitamins and minerals for: slowing the progression to later stages of AMD Decreasing the load of other modalities of treatment In 2017, there is no proven therapy to prevent or treat geographic atrophy
36 Guidelines For The Management of AMD TREATMENT MODALITIES
37 Visual Rehabilitation
38 Life Style Modification
39 ANTI-OXIDENTS Vitamins and Minerals Lutein/Zeaxanthin Omega -3 Fatty Acids
40 TREATMENT MODALITIES 9 No AMD Early AMD Intermediate AMD Advanced AMD (AREDS category 1) (AREDS category 2) (AREDS category 3) (AREDS category 4) No evidence to support the use of supplements No evidence to support the use of supplements Only 1.3% Advanced AMD The rate of development of advanced 5 y was 25% The risk of losing vision 3 lines (doubling of the visual angle) was 19 % 9. Davis MD, Gangnon RE, Lee LY, et al. Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report number 17. Arch Ophthalmol 2005;123:
41 TREATMENT MODALITIES 9 No AMD Early AMD Intermediate AMD Advanced AMD (AREDS category 1) (AREDS category 2) (AREDS category 3) (AREDS category 4) No evidence to support the use of supplements No evidence to support the use of supplements Only 1.3% Advanced AMD The rate of development of advanced 5 y was 25% The risk of losing vision 3 lines (doubling of the visual angle) was 19 % 9. Davis MD, Gangnon RE, Lee LY, et al. Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report number 17. Arch Ophthalmol 2005;123:
42 TREATMENT MODALITIES 9 No AMD Early AMD Intermediate AMD Advanced AMD (AREDS category 1) (AREDS category 2) (AREDS category 3) (AREDS category 4) No evidence to support the use of supplements No evidence to support the use of supplements Only 1.3% Advanced AMD The rate of development of advanced 5 y was 25% The risk of losing vision 3 lines (doubling of the visual angle) was 19 % 9. Davis MD, Gangnon RE, Lee LY, et al. Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report number 17. Arch Ophthalmol 2005;123:
43 TREATMENT MODALITIES 9 No AMD Early AMD Intermediate AMD Advanced AMD (AREDS category 1) (AREDS category 2) (AREDS category 3) (AREDS category 4) No evidence to support the use of supplements No evidence to support the use of supplements Only 1.3% Advanced AMD The rate of development of advanced 5 y was 25% The risk of losing vision 3 lines (doubling of the visual angle) was 19 % Only these two groups benefit from antioxidant vitamin and mineral supplementation 9. Davis MD, Gangnon RE, Lee LY, et al. Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report number 17. Arch Ophthalmol 2005;123:
44 TREATMENT MODALITIES Anti-VEGF (Aflibercept, Ranibizumab, Bevacizumab) are currently the preferred therapy to treat neovascular AMD over PDT and laser photocoagulation 10 This applies for subfoveal, juxtafoveal and extrafoveal lesions Heier JS et al. VIEW 1 and VIEW 2 Study group. Intravitreal aflibercept in wet age-related macular degeneration. Ophthalmology 2012;119: Schmidt-Erfurth U et al. Perspectives on verteporfin therapy combined with intravitreal corticosteroids. Arch Ophthalmol 2006;124: Kasier et al. DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in AMD: 12 months results. Ophthalmology 2012;119: Larsen M et al. MONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in AMD: 12 months results. Ophthalmology 2012;119: Koh et al. EVEREST Study: Efficacy and safety of verteporfin PDT in combination with ranibizumab or alone versus ranibizumab monotherapy in patints with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012;32:
45
46 Novel Treatments
47
48 Guidelines For The Management of AMD MANAGEMENT
49 MANAGEMENT 15 IN 2017 Patients who are currently smoking should be advised to stop Patients should be encouraged to assess their own visual acuity using monocular vision testing (i.e., Amsler grid) Education about methods of detecting new symptoms is crucial Need for promptly reporting new symptoms to an ophthalmologist Education about preventive regimens and the use of nutritional supplements (AREDS2) Electronic devices are now available to aid in the detection of neovascularization at early stage: Preferential Hyperacuity Perimetry 15. AREDS2-HOME Study Research Group, Chew EY, Clemons TE, Bressler, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization Home Monitoring of the eye (HOME) Study. Ophthalmology 2014;121:535-44
50 ForeseeHome Device Hyperacuity Visual Field Test Hyperacuity signals are briefly presented within the central visual field Patient s response to perceived distortion recorded using computer mouse Data is analysed in comparison to normative database and new visual field defects are identified.
51
52 MANAGEMENT 16 IN 2017 No AMD (AREDS category 1) Early AMD (AREDS category 2) RECOMMENDED TREATMENT Observation with no medical or surgical therapies Intermediate AMD (AREDS category 3) Advanced AMD (AREDS category 4) FOLLOW UP RECOMMENDATIONS Control group No or few small drusen (< 63μm) Multiple small drusen Few intermediate drusen ( μm) Mild RPE abnormalities Advanced AMD with bilateral subfoveal geographic atrophy or disciform scars Numerous intermediate drusen At lease one large druse ( 125 μm) Geographic atrophy of the RPE (Not involving the center of the fovea) Geographic atrophy of the RPE involving the center of the fovea Neovascular maculopathy: Return 6-24 mo if asymptomatic, or prompt exam for new symptoms suggestive of CNV CNV (pathologic angiogenesis from the choroidal vasculature extending the a defect in Bruch s membrane Serous/hemorrhagic detachement of NSR/RPE Retinal hard exudates Subretinal/sub-RPE fibrovascular proliferation Disciform scar OCT, FFA, Fundus Photos as appropriate 16. American Academy of Ophthalmology. Preferred Practice Pattern. Age-Related Macular Degeneration last update.
53 MANAGEMENT 16 IN 2017 RECOMMENDED No AMD TREATMENT Early AMD (AREDS Antioxidant category 1) vitamin and mineral supplements as recommended in the original AREDS/AREDS2 reports Control group No or few small drusen (< 63μm) (AREDS category 2) Multiple small drusen FOLLOW UP RECOMMENDATIONS Few intermediate drusen ( μm) Monitoring of monocular Mild RPE near abnormalities vision (reading/amsler grid) Return 6-24 mo if asymptomatic, or prompt exam for new symptoms suggestive of CNV Intermediate AMD (AREDS category 3) Numerous intermediate drusen At lease one large druse ( 125 μm) Geographic atrophy of the RPE (Not involving the center of the fovea) Advanced AMD (AREDS category 4) in one eye Geographic atrophy of the RPE involving the center of the fovea Neovascular maculopathy: CNV (pathologic angiogenesis from the choroidal vasculature extending the a defect in Bruch s membrane Serous/hemorrhagic detachement of NSR/RPE Retinal hard exudates Subretinal/sub-RPE fibrovascular proliferation Disciform scar 16. American Academy of Ophthalmology. Preferred Practice Pattern. Age-Related Macular Degeneration last update.
54 Guidelines For The Management of AMD CONCLUSION
55 Conclusion AMD is the leading cause of irreversible visual impairment in the developed countries Early detection and treatment are crucial to help preserve patients quality of live Smoking cessation is strongly recommended The use of nutritional supplements (AREDS2), when indicated, rate of development of advanced AMD by 25% in 5 years All patients should be educated about the prognosis of the disease and the potential value of treatment as appropriate for their visual and functional status Patients can be educated that while central visual loss is common, total visual loss is extremely rare hence the role of low vision aid
56 Conclusion AMD is the leading cause of irreversible visual impairment in the developed countries Early detection and treatment are crucial to help preserve patients quality of live Smoking cessation is strongly recommended The use of nutritional supplements (AREDS2), when indicated, rate of development of advanced AMD by 25% in 5 years All patients should be educated about the prognosis of the disease and the potential value of treatment as appropriate for their visual and functional status Patients can be educated that while central visual loss is common, total visual loss is extremely rare hence the role of low vision aid
57 Conclusion AMD is the leading cause of irreversible visual impairment in the developed countries Early detection and treatment are crucial to help preserve patients quality of live Smoking cessation is strongly recommended The use of nutritional supplements (AREDS2), when indicated, rate of development of advanced AMD by 25% in 5 years All patients should be educated about the prognosis of the disease and the potential value of treatment as appropriate for their visual and functional status Patients can be educated that while central visual loss is common, total visual loss is extremely rare hence the role of low vision aid
58 Conclusion AMD is the leading cause of irreversible visual impairment in the developed countries Early detection and treatment are crucial to help preserve patients quality of live Smoking cessation is strongly recommended The use of nutritional supplements (AREDS2), when indicated, rate of development of advanced AMD by 25% in 5 years All patients should be educated about the prognosis of the disease and the potential value of treatment as appropriate for their visual and functional status Patients can be educated that while central visual loss is common, total visual loss is extremely rare hence the role of low vision aid
59 Conclusion AMD is the leading cause of irreversible visual impairment in the developed countries Early detection and treatment are crucial to help preserve patients quality of live Smoking cessation is strongly recommended The use of nutritional supplements (AREDS2), when indicated, rate of development of advanced AMD by 25% in 5 years All patients should be educated about the prognosis of the disease and the potential value of treatment as appropriate for their visual and functional status Patients can be educated that while central visual loss is common, total visual loss is extremely rare hence the role of low vision aid
60 Conclusion AMD is the leading cause of irreversible visual impairment in the developed countries Early detection and treatment are crucial to help preserve patients quality of live Smoking cessation is strongly recommended The use of nutritional supplements (AREDS2), when indicated, rate of development of advanced AMD by 25% in 5 years All patients should be educated about the prognosis of the disease and the potential value of treatment as appropriate for their visual and functional status Patients can be educated that while central visual loss is common, total visual loss is extremely rare hence the role of low vision aid
AGE RELATED MACULAR DEGENERATION (AMD) PREFERRED PRACTICE PATTERNS (PPP) Philippines: 2016
AGE RELATED MACULAR DEGENERATION (AMD) PREFERRED PRACTICE PATTERNS (PPP) Philippines: 2016 The Age Related Macular Degeneration (AMD) Preferred Practice Patterns (PPP) Philippines: 2016 was prepared by
More informationPrevention and treatment of agerelated macular degeneration
THERAPY REVIEW Prevention and treatment of agerelated macular degeneration SARAH HORTON AND CATHERINE GULY Age-related macular degeneration (AMD) is a common cause of visual loss in older people and GPs
More informationClinical Trials Related to Age Related Macular Degeneration
Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad
More informationFluorescein Angiography
Last revision: October 2011 by Luis Arias Fluorescein Angiography Authors: Luis Arias, MD Hospital Universitari de Bellvitge - University of Barcelona. Spain Jordi Monés, MD Institut de la Màcula i de
More informationThe Foundation WHAT IS THE RETINA?
Age-Related Macular Degeneration (AMD) is a deterioration of the retina and choroid that leads to a substantial loss in visual acuity (sharpness of vision). AMD is the leading cause of significant visual
More informationPhotodynamic Therapy for Treatment of Subfoveal Choroidal Neovascularization in Exudative Age-Related Macular Degeneration
Clinical Medicine Journal Vol. 4, No. 4, 2018, pp. 60-66 http://www.aiscience.org/journal/cmj ISSN: 2381-7631 (Print); ISSN: 2381-764X (Online) Photodynamic Therapy for Treatment of Subfoveal Choroidal
More informationOphthalmology: Questions and Answers. Current Topics in Ophthalmology. Disclosures: Common Questions:
Current Topics in Ophthalmology Ophthalmology: Questions and Answers Jacque Duncan, MD Professor, Clinical Ophthalmology UCSF Primary Care Medicine: Principles and Practice October 30, 2013 With help from:
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationThe Age-Related Eye Disease Study
What have the Age-Related Eye Disease Study (AREDS) and AREDS2 Taught Us? Emily Y. Chew, MD National Eye Institute/National Institutes of Health On Behalf of the AREDS and AREDS2 Research Groups Presenter
More informationRetinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why?
Original Article Retinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why? Dr Sreelekha S. MS, DNB, DO, FRCS, Dr Manoj Soman DNB, FICO, FRCS, Dr. Unni Nair MS, FRCS, Dr. Ruminder
More informationCommon Causes of Vision Loss
Common Causes of Vision Loss Learning Objectives To identify the most common causes of vision loss in the United States To differentiate the most common forms of agerelated macular degeneration and diabetic
More information25% of normal 2/20/2018. Practical Guidelines for the Treatment of AMD 78% 22% Overview. AMD Information Overload
I am a consultant / or have financial interest in: Practical Guidelines for the Treatment of Maculogix J&J Acuvue Vision Source Ocusoft Pogo Tech Jeffrey W. Jones, OD Longview, TX 75605 jjoneseye@gmail.com
More informationP. Stavrakas MD PhD. Consultant Ophthalmologist and vitreoretinal surgeon 2 nd Department of Ophthalmology University of Athens
P. Stavrakas MD PhD Consultant Ophthalmologist and vitreoretinal surgeon 2 nd Department of Ophthalmology University of Athens Primary diagnose of exudative AMD Anti-VEGF monotherapy treatment Loss of
More informationA(REDS) to Z(inc) Nutrition for eye health
All eyes on the macula A(REDS) to Z(inc) Nutrition for eye health Professor Christine Purslow PhD, MCOptom, FBCLA, FIACLE Macula lutea = yellow spot Colour is determined by 3 carotenoids Lutein Zeaxanthin
More informationFood, Supplements and Healthy Lifestyles in Slowing and Preventing Macular Degeneration Julie Mares, Professor For the Nutrition and Eye Health Research Team http://nutritionforeyes.ophth.wisc.edu Preserving
More information11/29/2016 MACULAR MALADIES: TYPICAL & ATYPICAL CASES
MACULAR MALADIES: TYPICAL & ATYPICAL CASES Dawn Pewitt, OD, FAAO Triad Eye Institute, Grove, OK Dpewitt@triadeye.com Disclosure Statement: No financial disclosures COPE 51218-PS Please silence all mobile
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 9.03.08 Photodynamic Therapy for Choroidal Neovascularization 9.03.20 Intraocular Radiation Therapy for
More informationMONTHLY ADMINISTERED INTRAVITREOUS PHARmacotherapy
Polypoidal Choroidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab ALEXANDROS N. STANGOS, JAGDEEP SINGH GANDHI, JAYASHREE NAIR-SAHNI, HEINRICH HEIMANN,
More informationA population based study of macular choroidal neovascularization using optical coherence tomography in Eastern China
EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 371-376, 2014 A population based study of macular choroidal neovascularization using optical coherence tomography in Eastern China JIE ZHAO, JUN HU, HAO LU and
More informationRetina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014
Retina Conference Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014 Subjective CC/HPI: 64 year old Caucasian female referred by outside ophthalmologist
More informationPhotodynamic Therapy for Choroidal Neovascularization
Photodynamic Therapy for Choroidal Neovascularization Policy Number: 9.03.08 Last Review: 10/2014 Origination: 10/2000 Next Review: 10/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationA prospective nonrandomized clinical study on exudative age related macular degeneration
Original Article A prospective nonrandomized clinical study on exudative age related macular degeneration Ayakutty Muni Raja, Siddharam Janti, Charanya Chendilnathan, Adnan Matheen Department of Ophthalmology,
More informationVision loss in elderly. Erica Weir, April 2015
Vision loss in elderly Erica Weir, April 2015 1 Burden Enter nursing homes 3 years earlier Twice the risk of falling 4x the risk of hip fracture Independent risk factor for delirium What are the leading
More informationA Comparative Study of Age Related Macular Degeneration In Relation To SD-OCTand Fundus Photography.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 11 Ver. III (Nov. 2015), PP 33-37 www.iosrjournals.org A Comparative Study of Age Related Macular
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Medical Policy Manual Medicine, Policy No. 134 Intraocular Radiation Therapy for Age-Related Macular Degeneration Next Review: April 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER
More informationVision loss in elderly
Vision loss in elderly Erica Weir, February 2016 1 Burden Enter nursing homes 3 years earlier Twice the risk of falling 4x the risk of hip fracture Independent risk factor for delirium What are the leading
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationOriginal Policy Date
MP 9.03.08 Photocoagulation of Macular Drusen Medical Policy Section Miscellaneous Policies Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return
More informationThe Age Related Eye Disease Study
The Age Related Eye Disease Study Fatoumata Yanoga, MD Assistant Professor of Ophthalmology Ohio State University Wexner Medical Center 04/13/2018 No Relevant Financial Relationships with Commercial Interests
More informationDespite our growing knowledge of the
OVERVIEW OF AVAILABLE TREATMENTS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION * Carl D. Regillo, MD ABSTRACT Although potential treatments for neovascular age-related macular degeneration represent
More informationDescription. Section: Other Effective Date: July 15, Subsection: Vision Original Policy Date: December 7, 2011 Subject: Page: 1 of 23
Last Review Status/Date: June 2015 Page: 1 of 23 Description Photodynamic therapy (PDT) is a treatment modality designed to selectively occlude ocular choroidal neovascular tissue. The therapy is a 2-step
More informationManual. Manual Welsh Eye Care Initiative. A Welsh Eye Care Initiative. Protocol. The Assessment and Management of Age-related Macular Degeneration
A Protocol 1.0 Definitions The following terms are important in this text: Wet Macular Degeneration Condition caused by the growth of abnormal blood vessels under the retina. Symptoms appear suddenly and
More informationClinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283
Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important
More informationManagement of Neovascular AMD
Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationAge Related Macular Degeneration - An Overview Ajay Kapoor MS, Nishank Mittal MBBS, MS, Fel.(V.R.), Ankur Gupta MBBS, DNB,Fel.(V.R.
MEDICAL OPHTHALMOLOGY Age Related Macular Degeneration - An Overview Ajay Kapoor MS, Nishank Mittal MBBS, MS, Fel.(V.R.), Ankur Gupta MBBS, DNB,Fel.(V.R.) Age related macular degeneration (AMD) is one
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 9.03.20 Intraocular Radiation Therapy for Age-Related Macular Degeneration Photodynamic Therapy for Choroidal
More informationSpectral-domain Optical Coherence Tomography Imaging of Age-related Macular Degeneration
Imaging Spectral-domain Optical Coherence Tomography Imaging of Age-related Macular egeneration Carlos Alexandre de Amorim Garcia Filho, 1 Philip J Rosenfeld, 2 Zohar Yehoshua 3 and Giovanni Gregori 3
More informationSUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR
The following are summaries of selected presentations and posters from the American Society of Retina Specialists and European VitreoRetinal Society Annual Meeting held September 9 13, 2006, in Cannes,
More informationAge-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis)
Aggiornamento biotecnologico: MoAb anti VEGF Age-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis) Giulia Germena AMD DRY (non-neovascular) Atrophic cell death in the macula No leakage WET
More informationAge-Related Macular Degeneration (AMD)
Age-Related Macular Degeneration (AMD) What is the Macula? What is Dry AMD (Age-related Macular Degeneration)? Dry AMD is an aging process that causes accumulation of waste product under the macula leading
More informationAge-related Macular Degeneration (AMD) Update. Michael W. Stewart, MD Professor and Chairman Department of Ophthalmology Mayo Clinic Florida
Age-related Macular Degeneration (AMD) Update Michael W. Stewart, MD Professor and Chairman Department of Ophthalmology Mayo Clinic Florida Disclosure Alkahest Consultant Allergan Research Support Bayer
More informationMichael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015
Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015 So What Parts of the Eye Retina are Affected by VHL Neural tissue
More informationHHS Public Access Author manuscript Ophthalmic Surg Lasers Imaging Retina. Author manuscript; available in PMC 2016 January 14.
High-Speed Ultrahigh-Resolution OCT of Bruch s Membrane in Membranoproliferative Glomerulonephritis Type 2 Mehreen Adhi, MD, Sarah P. Read, MD, PhD, Jonathan J. Liu, PhD, James G. Fujimoto, PhD, and Jay
More informationRetinal Diseases. Age-Related Macular Degeneration. What Is AMD? Risk Factors for AMD
Santosh C. Patel, M.D. Retina Specialists The Latest And Greatest in the Management of Retinal Diseases February 13, 2007 Retinal Diseases Majority of Blindness in Civilized World AMD Diabetic Retinopathy
More informationDOME SHAPED MACULOPATHY. Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος
DOME SHAPED MACULOPATHY Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος DOME SHAPED MACULOPATHY-DEFINITIONS The entity Dome Shaped Macula ( DSM ) was first described by Gaucher and associates in 2008
More informationStabilization of visual acuity with photodynamic therapy in eyes with chorioretinal anastomoses
Graefe s Arch Clin Exp Ophthalmol (2004) 242:368 376 CLINICAL INVESTIGATION DOI 10.1007/s00417-003-0844-0 Rufino M. Silva José R. Faria de Abreu António Travassos José G. Cunha-Vaz Stabilization of visual
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More information연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과
연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과 40 Table. Clinical characteristics and results of patients undergoing photodynamic therapy for retinal angiomatous proliferation Patients No. Age/ sex Eye
More informationOptical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis
Optical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis G Pron August 2014 Ontario Health Technology Assessment Series; Vol. 14:
More informationThe Royal College of Ophthalmologists
The Royal College of Ophthalmologists Age-Related Macular Degeneration Guidelines for Management February 2009 Scientific Department The Royal College of Ophthalmologists 17 Cornwall Terrace Regent s Park
More informationGood News for The Macular Generation. Dr Andrew Thompson FRANZCO
Good News for The Macular Generation Dr Andrew Thompson FRANZCO Anti-VEGFs for wet MD are one of the greatest advances in medicine in past decade Prof. Gary Brown Director Wills Eye Institue Retina Service
More informationOptical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.
Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D. Disclosure OCT Optical Coherence Tomography No relevant financial relationships I will refer to
More informationMEDICAL POLICY SUBJECT: PHOTODYNAMIC THERAPY FOR EFFECTIVE DATE: 07/20/00 SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
MEDICAL POLICY SUBJECT: PHOTODYNAMIC THERAPY FOR PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationCurrent indications for photodynamic therapy in medical retina practice
réalités Current indications for photodynamic therapy in medical retina practice No. 254 September 2018 OPHTALMOLOGIQUES SUMMARY: In medical retina practice, the use of photodynamic therapy (PDT) revolutionised
More informationMacular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials Glenn J. Jaffe, MD, 1 Daniel F. Martin, MD, 2 Cynthia A. Toth, MD, 1 Ebenezer Daniel, MPH, PhD,
More informationThe College of Optometrists - Learning outcomes for the Professional Certificate in Medical Retina
Learning outcomes for the Professional Certificate in Medical Retina, incorporating diabetic retinopathy screening and age related macular degeneration The professional certificate is a prerequisite to
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #14 (NQF 0087): Age-Related Macular Degeneration (AMD): Dilated Macular Examination National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationAlthough photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION *
PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Evangelos S. Gragoudas, MD ABSTRACT In December 24, the US Food and Drug Administration (FDA) approved pegaptanib sodium. Pegaptanib
More informationOCT Angiography in Primary Eye Care
OCT Angiography in Primary Eye Care An Image Interpretation Primer Julie Rodman, OD, MS, FAAO and Nadia Waheed, MD, MPH Table of Contents Diabetic Retinopathy 3-6 Choroidal Neovascularization 7-9 Central
More informationMacular Degeneration. John Christoforidis, MD Susie Chang, MD. Assistant Professors Department of Ophthalmology Ohio State University
Macular Degeneration John Christoforidis, MD Susie Chang, MD Assistant Professors Department of Ophthalmology Ohio State University 1. Retina 2. Optic Chiasm 3. LGN 4. Temporal lobe Courtesy of Ben Glasgow,
More informationMild NPDR. Moderate NPDR. Severe NPDR
Diabetic retinopathy Diabetic retinopathy is the most common cause of blindness in adults aged 35-65 years-old. Hyperglycaemia is thought to cause increased retinal blood flow and abnormal metabolism in
More informationBilateral Elevated Macular Lesions
Challenging Case Bilateral Elevated Macular Lesions Section Editor: Alireza Ramezani, MD Case presentation A 65-year-old woman presented with decreased vision in both eyes of 2 months duration. She reported
More informationDepartment of Ophthalmology, Kim s Eye Hospital, Konyang University College of Medicine, Seoul, Korea 2
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2015;29(5):315-324 http://dx.doi.org/10.3341/kjo.2015.29.5.315 Original Article Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related
More informationUse of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes
Use of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes Daniel E. Charles, MD, Martin Charles, MD, Gisela Jelusich,
More informationIQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy Fawwaz Al Mamoori* Medical Retina Department, Eye Specialty Hospital,
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationDr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre
Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre 11:00-11:55 WS #115: The Revolution in Macular Degeneration Management 12:05-13:00 WS #127: The Revolution in Macular
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process
Quality ID #14 (NQF 0087): Age-Related Macular Degeneration (AMD): Dilated Macular Examination National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY
More informationTHE OCULAR histoplasmosis
CLINICAL SCIENCES Reactivation of Inflammatory Lesions in Ocular Histoplasmosis David Callanan, MD; Gary E. Fish, MD, JD; Rajiv Anand, MD Background: Active inflammation has not been traditionally associated
More informationThe Royal College of Ophthalmologists. Age-Related Macular Degeneration: Guidelines for Management
The Royal College of Ophthalmologists Age-Related Macular Degeneration: Guidelines for Management September 2013 [Click here to view the College Statement on choice of anti VEGF agents for wet AMD treatments
More informationInstudies of vascular endothelial growth factor
MONITORING THERAPEUTIC EFFICACY IN THE ANTI-VEGF ERA* SriniVas R. Sadda, MD ABSTRACT One of the most important questions with vascular endothelial growth factor (VEGF) inhibitors for age-related macular
More informationThe limited number of currently approved
CLINICAL TRIALS OF VERTEPORFIN AND PEGAPTANIB: WHAT ARE THE RESULTS? * William F. Mieler, MD ABSTRACT Currently available treatment options for the management of choroidal neovascularization (CNV) in age-related
More informationADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY. By: Chris Munnerlyn, OMT Student University of Arkansas for Medical Sciences
ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY By: Chris Munnerlyn, OMT Student University of Arkansas for Medical Sciences ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY (AOFVD) AOFVD is a condition that
More informationReducing vision loss in chronic eye disease
THEME vision at risk Anthony Fong MBBS, BOptom, is Clinical Fellow, City Eye Centre, Brisbane, Queensland. antfong@ hotmail.com Graham Lee MD, MBBS, FRANZCO, is Associate Professor, The University of Queensland.
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA68; The clinical and cost effectiveness of photodynamic therapy for age-related macular degeneration TA68 guidance
More informationI n the Western world, age related macular degeneration
207 SCIENTIFIC REPORT Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy F Gelisken, B A Lafaut, W Inhoffen, M Voelker, S Grisanti, K U Bartz-Schmidt...
More informationAge-related macular degeneration: diagnosis and management
Published Online xx, 2008 Age-related macular degeneration: diagnosis and management H. L. Cook, P. J. Patel, and A. Tufail Moorfields Eye Hospital, City Road, London EC1V 2PD, UK Introduction Accepted:
More informationOriginal Article Ranibizumab as needed therapy for wet age-related macular degeneration combined with serous pigment epithelial detachment
Int J Clin Exp Med 2016;9(7):13650-13656 www.ijcem.com /ISSN:1940-5901/IJCEM0026582 Original Article Ranibizumab as needed therapy for wet age-related macular degeneration combined with serous pigment
More informationSupplementary Online Content
Supplementary Online Content Koh A, Lai TYY, Takahashi K, et al; the EVEREST II Study Group. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal
More informationThe Role of Phenotype in Selectively Enriching Patients for Clinical Studies
The Role of Phenotype in Selectively Enriching Patients for Clinical Studies Developing Treatments for Dry Age-Related Macular Degeneration (AMD) Workshop November 15, 2014 National Academy of Sciences
More informationZEISS AngioPlex OCT Angiography. Clinical Case Reports
Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy
More informationClinical Policy Title: Ocular photodynamic therapy (OPDT) with Visudyne (verteporfin) for macular degeneration treatment
Clinical Policy Title: Ocular photodynamic therapy (OPDT) with Visudyne (verteporfin) for macular degeneration treatment Clinical Policy Number: 10.02.04 Effective Date: January 1, 2016 Initial Review
More informationEfficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration
Efficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration Marilita M. Moschos Abstract- Purpose: To evaluate by OCT and mf-erg the macular function in eyes with CNV due to ARMD
More informationDepartment of Ophthalmology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea
Department of Ophthalmology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea Purpose: To investigate the factors that affect final vision following photodynamic therapy
More informationThe Natural History of Occult Choroidal Neovascularisation Associated With Age-related Macular Degeneration. A Systematic Review
Review Article 145 The Natural History of Occult Choroidal Neovascularisation Associated With Age-related Macular Degeneration. A Systematic Review Antonio Polito, 1 MD, Miriam Isola, 2 MHS, Paolo Lanzetta,
More informationCATARACT IS THE LEADING
CLINICAL SCIENCES Progression of Age-Related Macular Degeneration After Cataract Surgery Li Ming Dong, PhD; Walter J. Stark, MD; Joan L. Jefferys, ScM; Selwa Al-Hazzaa, MD; Susan B. Bressler, MD; Sharon
More informationThinking Beyond Wet Age-Related Macular Degeneration
Ophthalmic Deliberations ISSN 0972-0200 Thinking Beyond Wet Age-Related Macular Degeneration Neha Goel, Atul Kumar, Mahesh P Shanmugam, Muna Bhende, Raja Narayanan, Hidetaka Matsumoto Atul Kumar MD, FAMS
More informationWet AMD. dept headline headline. headline headline. From Start to Finish
Wet AMD dept headline headline From Start to Finish headline headline Deck Anti-VEGF therapy for patients with wet AMD is a standard of care that saves sight for thousands of people each year. dept byline
More informationDownloaded from:
Evans, JR; Lawrenson, JG (2013) Dietary interventions for AMD: what do we know and what do we not know? The British journal of ophthalmology. ISSN 0007-1161 DOI: https://doi.org/10.1136/bjophthalmol- 2013-303134
More informationAngio-OCT. Degenerazione Maculare Legata all Eta. Giuseppe Querques
Angio-OCT Degenerazione Maculare Legata all Eta Giuseppe Querques Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita Salute San Raffaele, Milan, Italy Financial Disclosure ADVISORY
More informationClinical Trial Endpoints for Macular Diseases
Clinical Trial Endpoints for Macular Diseases Developed in collaboration Learning Objective Upon completion, participants should be able to: Summarize types of biomarkers of progression and treatment response
More informationFundus Autofluorescence. Jonathan A. Micieli, MD Valérie Biousse, MD
Fundus Autofluorescence Jonathan A. Micieli, MD Valérie Biousse, MD The retinal pigment epithelium (RPE) has many important functions including phagocytosis of the photoreceptor outer segments Cone Rod
More informationFROM OUTDATED TO UPDATED Eminence-Based Medicine
FROM OUTDATED TO UPDATED Eminence-Based Medicine Evidence-Based Medicine A REVIEW OF KEY CLINICAL TRIALS Anthony DeWilde, OD FAAO 1 EMINENCE BASED MEDICINE 2 EVIDENCE BASED MEDICINE 3 4 CLINICAL TRIALS
More informationPolypoidal choroidal vasculopathy and photodynamic therapy with verteporfin
Graefe s Arch Clin Exp Ophthalmol (2005) 243: 973 979 CLINICAL INVESTIGATION DOI 10.1007/s00417-005-1139-4 Rufino M. Silva João Figueira M. Luz Cachulo Liliane Duarte José R. Faria de Abreu J. G. Cunha-Vaz
More informationCorinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist
Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist PRESENT PROFESSIONAL POSITION OPHTALMOLOGIST DOCTOR, Private practice Retinal medical Specialist, DMLA in particular Installation year
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Intraocular Radiation Therapy for Age-Related Macular Degeneration Policy Number: 9.03.20 Last Review: 9/2014 Origination: 9/2008 Next Review: 9/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationSince /01/2014 Private practice Ophthalmology, Retinal Medical Specialty and AMD, private office
Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist SELARL CABINET DOCTEUR GONZALEZ 27, Boulevard des Minimes 31 200 Toulouse! 05 34 40 77 30 e-mail : cabinet.dr.gonzalez@wanadoo.fr Fax
More informationNATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS
NATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS JAE HUI KIM, MD,* YOUNG SUK CHANG, MD, JONG WOO KIM, MD* Purpose: To
More informationDepartment of Ophthalmology, University Hospital of Santiago de Compostela, Ramon Baltar S/N, Santiago de Compostela, Spain 2
Case Reports in Medicine Volume 2012, Article ID 897097, 10 pages doi:10.1155/2012/897097 Case Report Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy
More information